Eris Lifesciences will be able to take 10 percent market share in the insulin market, Amit Bakshi, chairman and managing director, told CNBC-TV18.
He also expects a doubling of the insulin market in the coming years.
Also Read: Eris Lifesciences stock soars 10% on tie-up with MJ Biopharm to enter insulin market
The pharma company has signed a joint venture with MJ Biopharm for the insulin market.
For the entire interview, watch the video